Hard but Hopeful: the Clinical and Translational Research Progress in Pancreatic Cancer
| Author | : Taiping Zhang |
| Publisher | : Frontiers Media SA |
| Total Pages | : 152 |
| Release | : 2022-11-04 |
| Genre | : Medical |
| ISBN | : 283250387X |
Hard But Hopeful The Clinical And Translational Research Progress In Pancreatic Cancer
Download Hard But Hopeful The Clinical And Translational Research Progress In Pancreatic Cancer full books in PDF, epub, and Kindle. Read online free Hard But Hopeful The Clinical And Translational Research Progress In Pancreatic Cancer ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
Translational Pancreatic Cancer Research
| Author | : Christoph W. Michalski |
| Publisher | : Springer Nature |
| Total Pages | : 252 |
| Release | : 2020-07-31 |
| Genre | : Medical |
| ISBN | : 3030494764 |
This book incorporates a multi-disciplinary approach to present how research results can be translated into clinical trials. The first part begins with a chapter on variants of pancreatic cancer, precursor lesions and groups of people at risk to developing the disease. There is a particular focus on intraductal papillary mucinous neoplasia as a large-scale clinical challenge in pancreatology. The next two parts focus on diagnosis, biomarkers and stratification that emphasize how various approaches to biomarker development are important as both prognostic and predictive tools. The final part consists of personalized treatment approaches that include preclinical models of pancreatic cancer and stromal, epigenetic and metabolism targeting as promising approaches to be translated into early phase clinical trials. Chapters within this part also deal with approaches that are close to being implemented in clinical practice or are already being tested in (early) clinical trials, such as those that targeting the immune systems and strategies to overcome immunotherapy resistance; phase 1 clinical trials and translational approaches in surgical treatment. Written by experts in their fields, Translational Pancreatic Cancer Research provides an outlook towards future directions by integrating information both from basic and clinical research and though demonstrating pathways to better understanding pancreatic cancer and current approaches to translating these into clinical practice.
The Exocrine Pancreas
| Author | : Stephen Pandol |
| Publisher | : Morgan & Claypool Publishers |
| Total Pages | : 66 |
| Release | : 2011 |
| Genre | : Medical |
| ISBN | : 1615041389 |
The secretions of the exocrine pancreas provide for digestion of a meal into components that are then available for processing and absorption by the intestinal epithelium. Without the exocrine pancreas, malabsorption and malnutrition result. This chapter describes the cellular participants responsible for the secretion of digestive enzymes and fluid that in combination provide a pancreatic secretion that accomplishes the digestive functions of the gland. Key cellular participants, the acinar cell and the duct cell, are responsible for digestive enzyme and fluid secretion, respectively, of the exocrine pancreas. This chapter describes the neurohumoral pathways that mediate the pancreatic response to a meal as well as details of the cellular mechanisms that are necessary for the organ responses, including protein synthesis and transport and ion transports, and the regulation of these responses by intracellular signaling systems. Examples of pancreatic diseases resulting from dysfunction in cellular mechanisms provide emphasis of the importance of the normal physiologic mechanisms.
Mentor Training for Clinical and Translational Researchers
| Author | : Christine Pfund |
| Publisher | : W. H. Freeman |
| Total Pages | : 0 |
| Release | : 2013-01-25 |
| Genre | : Science |
| ISBN | : 9781464152740 |
The mentoring curriculum presented in this manual is adapted from Entering Mentoring by Jo Handelsman, Christine Pfund, Sarah Miller and Christine Maidl Pribbenow. The materials presented in Entering Mentoring provide the basis for research mentor training tailored to the needs of diverse mentors and mentees in various settings.
microRNA: Cancer
| Author | : Gaetano Santulli |
| Publisher | : Springer |
| Total Pages | : 242 |
| Release | : 2015-12-11 |
| Genre | : Science |
| ISBN | : 3319237306 |
This volume thoroughly explores of the functional role of microRNAs in cancer. It not only expertly describes the molecular mechanisms underlying the malignant transformation process but also compiles cutting-edge research on microRNAs in several forms of cancer, including colorectal cancer, pancreatic cancer, leukemia/lymphoma, prostate cancer, lung cancer, ovarian cancer, and bone cancer. Distinguished experts, currently working in prestigious institutions, elegantly discuss these fundamental themes. The text, which opens with a foreword by the renowned Dr. Carlo M. Croce, is enhanced by abundant color photographs, schemes, diagrams, and tables that fully support and complement the content. microRNA: Cancer is an ideal companion to both microRNA: Basic Science andmicroRNA: Medical Evidence. Taken together, these three books provide a state-of-the-art overview of this rapidly-expanding and fascinating field, from the molecular level to clinical practice. It will be invaluable to medical students, physicians, and researchers, as a complete and unique guide in the exploration of microRNA in basic science, cancer and clinical practice.
Integrative Pancreatic Intervention Therapy
| Author | : Ligong Lu |
| Publisher | : Elsevier |
| Total Pages | : 635 |
| Release | : 2020-09-12 |
| Genre | : Science |
| ISBN | : 0128194030 |
Integrative Pancreatic Intervention Therapy: A Holistic Approach summarizes, in a systematic manner, the diagnosis and treatment of late, critical pancreatic diseases. The book gives insights into each interventional technique, with an ultimate goal of improving survival rates for late stage pancreatic cancer patients. Six sections cover basic and transformation research on pancreatic diseases, interventional therapy for benign pancreatic disease, interventional therapy for malignant pancreatic diseases, interventional therapy for pancreative cancer-related lesions, stem cell and targeted molecular therapy for pancreative carcinoma, and combined interventional therapy for pancreative carcinoma. This book will be useful for those looking to understand how best to apply interventional therapy for the improvement of late state pancreatic cancer treatment. - Gives a step-by-step account of interventional therapy in late stage pancreatic cancer - Presents research on interventional techniques for plotting a management plan for late stage pancreatic cancer patients - Provides fundamental research in pancreatic cancer on the genes and signaling pathways relating to tumorigenesis and metastasis of advanced pancreatic cancer - Considers the combination of different interventional techniques to achieve better survival rates and increase quality of life for patients - Assesses the usefulness of combining interventional therapies into a holistic treatment approach
The Drug Development Paradigm in Oncology
| Author | : National Academies of Sciences, Engineering, and Medicine |
| Publisher | : National Academies Press |
| Total Pages | : 145 |
| Release | : 2018-02-12 |
| Genre | : Medical |
| ISBN | : 0309457971 |
Advances in cancer research have led to an improved understanding of the molecular mechanisms underpinning the development of cancer and how the immune system responds to cancer. This influx of research has led to an increasing number and variety of therapies in the drug development pipeline, including targeted therapies and associated biomarker tests that can select which patients are most likely to respond, and immunotherapies that harness the body's immune system to destroy cancer cells. Compared with standard chemotherapies, these new cancer therapies may demonstrate evidence of benefit and clearer distinctions between efficacy and toxicity at an earlier stage of development. However, there is a concern that the traditional processes for cancer drug development, evaluation, and regulatory approval could impede or delay the use of these promising cancer treatments in clinical practice. This has led to a number of effortsâ€"by patient advocates, the pharmaceutical industry, and the Food and Drug Administration (FDA)â€"to accelerate the review of promising new cancer therapies, especially for cancers that currently lack effective treatments. However, generating the necessary data to confirm safety and efficacy during expedited drug development programs can present a unique set of challenges and opportunities. To explore this new landscape in cancer drug development, the National Academies of Sciences, Engineering, and Medicine developed a workshop held in December 2016. This workshop convened cancer researchers, patient advocates, and representatives from industry, academia, and government to discuss challenges with traditional approaches to drug development, opportunities to improve the efficiency of drug development, and strategies to enhance the information available about a cancer therapy throughout its life cycle in order to improve its use in clinical practice. This publication summarizes the presentations and discussions from the workshop.
Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy
| Author | : |
| Publisher | : Academic Press |
| Total Pages | : 226 |
| Release | : 2019-02-26 |
| Genre | : Science |
| ISBN | : 0128176628 |
Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy edited by Dr. Nagaraju, PhD., DSc. focuses on overriding the resistance from chemotherapeutic drugs with a broader range of treatment options. It particularly focuses on stroma, tumor microenvironment, stem cells, stellate cells, transcription factors, growth factors, and important signaling pathways. This volume discusses topics such as pancreatic cancer biology, current therapeutic options, EMT, chemotherapy resistance mechanisms, and genetic manipulations and natural products to enhance the sensitivity of pancreatic cancer to chemotherapy. Additionally, it discusses small targeted molecules and pancreatic cancer trials, and nanotechnology-based drug delivery. Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy is a valuable source for researchers and advanced students in cancer and oncology as well as clinicians and medical students who are interested in learning more about ways to break pancreatic cancer resistance to chemotherapy. - Modulates the biologic properties of stroma in pancreatic cancer by targeting the several chemotherapy resistance mechanisms to impede their malignant property by introducing new strategies and drugs - Provides information about on-going research as well as clinical data on pancreatic cancer and detailed descriptions about therapeutic options for easy understanding - Utilizes full color figures to help the understanding of the content and tables for easy comparison of information as well as quick access to it
Integrating Clinical and Translational Research Networks—Building Team Medicine
| Author | : Ravi Salgia |
| Publisher | : MDPI |
| Total Pages | : 250 |
| Release | : 2021-01-29 |
| Genre | : Medical |
| ISBN | : 303650396X |
Medical centers are widely recognized as vital components of the healthcare system. However, academic medical centers are differentiated from their community counterparts by their mission, which typically focuses on clinical care, education, and research. Nonetheless, community clinics/hospitals fill a critical need and play a complementary role serving as the primary sites for health care in most communities. Furthermore, it is now increasingly recognized that in addition to physicians, physician-scientists, and other healthcare-related professionals, basic research scientists also contribute significantly to the emerging inter- and cross-disciplinary, team-oriented culture of translational science. Therefore, approaches that combine the knowledge, skills, experience, expertise, and visions of clinicians in academic medical centers and their affiliated community centers and hospitals, together with basic research scientists, are critical in shaping the emerging culture of translational research so that patients from the urban as well as suburban settings can avail the benefits of the latest developments in science and medicine. ‘Integrating Clinical and Translational Research Networks—Building Team Medicine’ is an embodiment of this ethos at the City of Hope National Medical Center in Duarte, California. It includes a series of papers authored by teams of leading clinicians, basic research scientists, and translational researchers. The authors discuss how engaging and collaborating with community-based practices, where the majority of older patients with cancer receive their care, can ensure that these patients receive the highest-quality, evidence-based care. Based on our collective experience at City of Hope, we would like to stress that the success of academic-community collaborative programs not only depends on the goodwill and vision of the participants but also on the medical administration, academic leadership, and policymakers who define the principles and rules by which cooperation within the health care industry occurs. We trust that our experience embodied in this singular compendium will serve as a ‘Rosetta Stone’ for other institutions and practitioners.
Hepatobiliary Cancers: Translational Advances and Molecular Medicine
| Author | : |
| Publisher | : Academic Press |
| Total Pages | : 468 |
| Release | : 2022-08-10 |
| Genre | : Science |
| ISBN | : 0323983936 |
Hepatobiliary cancer refers to primary malignant tumors originating in cells of the liver, bile ducts, and gallbladder. Globally, primary liver cancer, which includes hepatocellular carcinoma (~75 % of all cases) and intrahepatic biliary cancer or cholangiocarcinoma (~10-15 % 0f all cases) is the 6th most commonly diagnosed cancer and 3rd leading cause of cancer deaths worldwide. The vast majority of these highly malignant cancers are diagnosed at an advanced stage where treatment options are limited and patient survival outcomes are poor. The biological and therapeutic challenges posed by hepatobililiary cancers such as hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) are daunting, emphasizing a critical need to review and assess current and evolving basic, translational, and clinical research focused on addressing the critical obstacles that continue to limit progress towards achieving significant improvements in HCC and CCA clinical management and patient survival outcomes. Towards this goal, this special edition of Advances in Cancer Research is focused on providing a comprehensive, timely and authoritative reviews covering such topics of significant scientific and clinical relevance, including hepatobiliary cancer risk mechanisms and risk-predictive molecular biomarkers; causes and functional intricacies of inter- and intratumor heterogeneity; novel insights into the role of tumor microenvironment and key signaling pathways in promoting hepatobiliary cancer progression, therapeutic resistance and immunosuppression; emerging biomarkers of HCC and CCA prognosis; advances in molecular genomics for personalizing tumor classification and targeted therapies; innovative preclinical cell culture modeling for hepatobiliary cancer drug discovery; and current and emerging trends in hepatobiliary cancer molecular therapeutic targeting and immunotherapies. - Up-to date review of hepatobiliary cancers molecular genetics, novel predictive molecular biomarkers, and distinct mechanisms of inter-and intratumor heterogeneity - Novel insights into the role of tumor microenvironment as a promoter of hepatobiliary cancer progression and therapeutic resistance, as well as an emerging therapeutic target - Current and emerging approaches and strategies for advancing personalized molecular therapeutic targeting and immunotherapy of hepatobiliary cancers
